GlassScriptPhysician profile
Laura Murphy Bleekrode
NPI 1407927809
$18,822.66
in general payments reported to CMS, 2019-2025
24 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $254 · 2021: $587 · 2022: $409 · 2023: $506 · 2024: $538 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,910 · Travel and Lodging: $1,342 · Consulting Fee: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,020.00 |
| Food and Beverage | $1,909.80 |
| Travel and Lodging | $1,342.44 |
| Consulting Fee | $1,085.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $16,195.37 | 2023-2025 | Skyclarys, Spinraza, Skyclarys |
| Corium, LLC | $366.22 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $259.34 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $243.14 | 2019-2022 | |
| Cranial Technologies, INC | $232.70 | 2020-2025 | Doc Band |
| Kaleo, INC. | $205.55 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $205.07 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Neurelis, INC. | $187.82 | 2020-2024 | Valtoco |
| Sanofi Pasteur INC. | $150.37 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $141.48 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $140.26 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sanofi-Aventis U.S. LLC | $135.48 | 2024-2025 | |
| Adlon Therapeutics L.P. | $79.62 | 2019-2021 | |
| Phadia US INC. | $54.47 | 2022-2024 | Immunocap |
| Arbor Pharmaceuticals, INC. | $39.88 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $27.74 | 2019 | |
| Glaxosmithkline, LLC. | $26.01 | 2025 | Pediarix, Bexsero, Penmenvy |
| Ultragenyx Pharmaceutical INC. | $24.73 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $23.14 | 2025 | Neffy |
| Shire North American Group INC | $20.10 | 2019 | |
| Noven Therapeutics, LLC | $18.03 | 2023 | Xelstrym |
| Verrica Pharmaceuticals INC. | $17.60 | 2023 | Ycanth |
| Lnhc, INC | $14.50 | 2025 | Zelsuvmi |
| Collegium Pharmaceutical, INC. | $14.04 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bleekrode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.